|
TAF 25 mg (n=710)
|
TAF 10 mg (n=303)
|
TDF (n=219)
|
Non-TAF/TDF (n=420)
|
TAF 10 mg
|
TDF
|
Non-TAF/TDF
|
| Age at index date (y), mean±SD [median] |
49.7±13.7 [52.0] |
50.2±12.8 [53.0] |
49.9±13.2 [52.0] |
51.3±13.0 [52.0] |
3.6% |
(0.61) |
1.5% |
(0.85) |
11.6% |
(0.06) |
| Age categories (y), n (%) |
|
|
|
|
|
|
|
|
|
|
| 18-24 |
28 (3.9) |
8 (2.6) |
3 (1.4) |
5 (1.2) |
7.3% |
(0.61) |
16.1% |
(0.40) |
17.5% |
(0.10) |
| 25-34 |
96 (13.5) |
38 (12.5) |
31 (14.2) |
46 (11.0) |
2.9% |
1.8% |
7.8% |
| 35-44 |
116 (16.3) |
47 (15.5) |
43 (19.6) |
76 (18.1) |
2.3% |
8.6% |
4.7% |
| 45-54 |
173 (24.4) |
78 (25.7) |
48 (21.9) |
110 (26.2) |
3.2% |
5.8% |
4.2% |
| 55-64 |
198 (27.9) |
97 (32.0) |
65 (29.7) |
122 (29.0) |
9.0% |
4.0% |
2.6% |
| ≥65 |
99 (13.9) |
35 (11.6) |
29 (13.2) |
61 (14.5) |
7.2% |
2.0% |
1.7% |
| Female, n (%) |
188 (26.5) |
88 (29.0) |
67 (30.6) |
116 (27.6) |
5.7% |
(0.40) |
9.1% |
(0.23) |
2.6% |
(0.68) |
| Race, n (%) |
|
|
|
|
|
|
|
|
|
|
| White |
279 (39.3) |
101 (33.3) |
73 (33.3) |
148 (35.2) |
12.4% |
(0.14) |
12.4% |
(0.59) |
8.4% |
(0.43) |
| Black |
203 (28.6) |
106 (35.0) |
66 (30.1) |
125 (29.8) |
13.8% |
3.4% |
2.6% |
| Hispanic |
48 (6.8) |
20 (6.6) |
17 (7.8) |
28 (6.7) |
0.6% |
3.9% |
0.4% |
| Other |
20 (2.8) |
4 (1.3) |
6 (2.7) |
8 (1.9) |
10.5% |
0.5% |
6.0% |
| Unknown |
160 (22.5) |
72 (23.8) |
57 (26.0) |
111 (26.4) |
2.9% |
8.2% |
9.1% |
| Insurance plan type, n (%) |
|
|
|
|
|
|
|
|
|
|
| Insurance plan available |
570 (80.3) |
246 (81.2) |
171 (78.1) |
344 (81.9) |
2.3% |
(0.74) |
5.4% |
(0.48) |
4.1% |
(0.50) |
| Commercial |
395 (69.3) |
170 (69.1) |
110 (64.3) |
241 (70.1) |
0.4% |
(0.72) |
10.6% |
(0.12) |
1.7% |
(0.28) |
| Medicare |
99 (17.4) |
39 (15.9) |
26 (15.2) |
56 (16.3) |
4.1% |
5.9% |
2.9% |
| Medicaid |
59 (10.4) |
26 (10.6) |
25 (14.6) |
29 (8.4) |
0.7% |
12.9% |
6.6% |
| Other |
17 (3.0) |
11 (4.5) |
10 (5.8) |
18 (5.2) |
7.9% |
14.0% |
11.4% |
| US geographic region, n (%) |
|
|
|
|
|
|
|
|
|
|
| South |
417 (58.7) |
169 (55.8) |
126 (57.5) |
240 (57.1) |
6.0% |
(0.81) |
2.4% |
(0.95) |
3.2% |
(0.85) |
| West |
141 (19.9) |
62 (20.5) |
42 (19.2) |
92 (21.9) |
1.5% |
1.7% |
5.0% |
| Northeast |
82 (11.5) |
39 (12.9) |
28 (12.8) |
48 (11.4) |
4.0% |
3.8% |
0.4% |
| Midwest |
57 (8.0) |
29 (9.6) |
20 (9.1) |
35 (8.3) |
5.4% |
3.9% |
1.1% |
| Unknown |
13 (1.8) |
4 (1.3) |
3 (1.4) |
5 (1.2) |
4.1% |
3.7% |
5.3% |
| Year of index date, n (%) |
|
|
|
|
|
|
|
|
|
|
| 2018 |
215 (30.3) |
144 (47.5) |
95 (43.4) |
162 (38.6) |
35.9% |
(<0.001*) |
27.4% |
(<0.001*) |
17.5% |
(0.004*) |
| 2019 |
495 (69.7) |
159 (52.5) |
124 (56.6) |
258 (61.4) |
35.9% |
27.4% |
17.5% |
| Number of mental health-related comorbidities,b mean±SD [median] |
0.5±1.0 [0.0] |
0.3±0.8 [0.0] |
0.4±0.9 [0.0] |
0.5±1.0 [0.0] |
15.8% |
(0.02*) |
6.3% |
(0.39) |
1.8% |
(0.76) |
| Symptomatic HIV and AIDS |
193 (27.2) |
77 (25.4) |
52 (23.7) |
124 (29.5) |
4.0% |
(0.56) |
7.9% |
(0.31) |
5.2% |
(0.40) |
| Quan-CCI,c mean±SD [median] |
1.9±2.9 [0.0] |
1.8±2.9 [0.0] |
1.7±2.9 [0.0] |
2.2±3.2 [0.0] |
2.7% |
(0.69) |
5.1% |
(0.51) |
10.5% |
(0.09) |
| Hypertension |
108 (15.2) |
41 (13.5) |
28 (12.8) |
73 (17.4) |
4.8% |
(0.49) |
7.0% |
(0.38) |
5.9% |
(0.34) |
| Type 2 diabetes mellitus |
38 (5.4) |
25 (8.3) |
12 (5.5) |
25 (6.0) |
11.5% |
(0.08) |
0.6% |
(0.94) |
2.6% |
(0.67) |
| Pre-diabetes |
17 (2.4) |
5 (1.7) |
6 (2.7) |
9 (2.1) |
5.3% |
(0.46) |
2.2% |
(0.77) |
1.7% |
(0.79) |
| Patients with a BMI measurement, n (%) |
703 (99.0) |
299 (98.7) |
217 (99.1) |
411 (97.9) |
3.1% |
(0.64) |
0.7% |
(0.92) |
9.3% |
(0.11) |
|
BMI (kg/m2), mean±SD [median]
|
28.3±6.2 [27.1] |
28.9±8.9 [27.5] |
28.5±6.1 [27.7] |
28.0±5.8 [27.1] |
8.2% |
(0.27) |
2.9% |
(0.71) |
4.4% |
(0.48) |
|
BMI categories (kg/m2), n (%)
|
|
|
|
|
|
|
|
|
|
|
| <25 |
225 (32.0) |
92 (30.8) |
64 (29.5) |
131 (31.9) |
2.7% |
(0.92) |
5.4% |
(0.79) |
0.3% |
(0.56) |
| 25-29 |
247 (35.1) |
104 (34.8) |
82 (37.8) |
157 (38.2) |
0.7% |
5.5% |
6.4% |
| 30-34 |
130 (18.5) |
55 (18.4) |
37 (17.1) |
75 (18.2) |
0.3% |
3.8% |
0.6% |
| ≥35 |
101 (14.4) |
48 (16.1) |
34 (15.7) |
48 (11.7) |
4.7% |
3.6% |
8.0% |
| Patients with a weight measurement, n (%) |
710 (100.0) |
303 (100.0) |
219 (100.0) |
420 (100.0) |
— |
— |
— |
— |
— |
— |
|
Weight (kg), mean±SD [median]
|
84.2±18.7 [82.1] |
85.1±20.7 [81.9] |
83.8±19.1 [81.9] |
83.6±18.1 [81.7] |
4.7% |
(0.50) |
1.9% |
(0.81) |
3.1% |
(0.62) |
| Index regimen, n (%) |
|
|
|
|
|
|
|
|
|
|
| PI-based |
27 (3.8) |
39 (12.9) |
9 (4.1) |
7 (1.7) |
33.3% |
(<0.001*) |
1.6% |
(0.84) |
13.1% |
(0.04*) |
| Darunavir-based |
21 (3.0) |
39 (12.9) |
8 (3.7) |
7 (1.7) |
37.4% |
(<0.001*) |
3.9% |
(0.61) |
8.6% |
(0.18) |
| Atazanavir-based |
6 (0.8) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
— |
— |
4.8% |
(0.56) |
— |
— |
| INSTI-based |
591 (83.2) |
264 (87.1) |
99 (45.2) |
418 (99.5) |
11.0% |
(0.12) |
86.4% |
(<0.001*) |
60.6% |
(<0.001*) |
| Dolutegravir-based |
102 (14.4) |
0 (0.0) |
19 (8.7) |
413 (98.3) |
— |
— |
17.9% |
(0.03*) |
318.0% |
(<0.001*) |
| Elvitegravir-based |
0 (0.0) |
264 (87.1) |
52 (23.7) |
0 (0.0) |
— |
— |
— |
— |
— |
— |
| Raltegravir-based |
19 (2.7) |
0 (0.0) |
28 (12.8) |
5 (1.2) |
— |
— |
38.5% |
(<0.001*) |
10.8% |
(0.09) |
| Bictegravir-based |
470 (66.2) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
— |
— |
— |
— |
— |
— |
| NNRTI-based |
92 (13.0) |
0 (0.0) |
111 (50.7) |
82 (19.5) |
— |
— |
88.6% |
(<0.001*) |
17.9% |
(0.003*) |
| Doravirine-based |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
— |
— |
— |
— |
— |
— |
| Efavirenz-based |
3 (0.4) |
0 (0.0) |
76 (34.7) |
0 (0.0) |
— |
— |
100.9% |
(<0.001*) |
— |
— |
| Rilpivirine-based |
89 (12.5) |
0 (0.0) |
35 (16.0) |
82 (19.5) |
— |
— |
9.9% |
(0.19) |
19.1% |
(0.002*) |
| Use of at least one medication associated with weight change,d n (%) |
229 (32.3) |
97 (32.0) |
59 (26.9) |
128 (30.5) |
0.5% |
(0.94) |
11.7% |
(0.14) |
3.8% |
(0.54) |